Iron Chelation Therapy
Overview
flowchart TD
Iron["Iron"] -->|"causes"| Phospholipid_Peroxidation["Phospholipid Peroxidation"]
Iron["Iron"] -->|"involved in"| Neurotransmitter_Synthesis["Neurotransmitter Synthesis"]
Iron["Iron"] -->|"involved in"| Mitochondrial_Metabolism["Mitochondrial Metabolism"]
iron["iron"] -->|"drives"| ferroptosis["ferroptosis"]
iron["iron"] -->|"binds"| FTH1["FTH1"]
Iron["Iron"] -->|"causes"| Ferroptosis["Ferroptosis"]
Iron["Iron"] -->|"mediates"| Ferroptosis["Ferroptosis"]
Iron["Iron"] -->|"involved in"| Ferroptosis["Ferroptosis"]
Iron["Iron"] -->|"involved in"| Myelination["Myelination"]
Iron["Iron"] -->|"causes"| Oxidative_Stress["Oxidative Stress"]
iron["iron"] -->|"mediates"| oxidative_stress["oxidative stress"]
iron["iron"] -->|"binds"| FTMT["FTMT"]
Iron["Iron"] -->|"associated with"| Microglia["Microglia"]
Iron["Iron"] -->|"associated with"| Ferroptosis["Ferroptosis"]
style IRON fill:#4fc3f7,stroke:#333,color:#000
<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Iron Chelation Therapy</th>
</tr>
<tr>
<td class="label">Agent</td>
<td>Loading Dose</td>
</tr>
<tr>
<td class="label">Deferoxamine</td>
<td>40 mg/kg/day</td>
</tr>
<tr>
<td class="label">Deferasirox</td>
<td>20 mg/kg/day</td>
</tr>
<tr>
<td class="label">Deferiprone</td>
<td>20 mg/kg/day</td>
</tr>
</table>
...Iron Chelation Therapy
Overview
Mermaid diagram (expand to render)
<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Iron Chelation Therapy</th>
</tr>
<tr>
<td class="label">Agent</td>
<td>Loading Dose</td>
</tr>
<tr>
<td class="label">Deferoxamine</td>
<td>40 mg/kg/day</td>
</tr>
<tr>
<td class="label">Deferasirox</td>
<td>20 mg/kg/day</td>
</tr>
<tr>
<td class="label">Deferiprone</td>
<td>20 mg/kg/day</td>
</tr>
</table>
Iron Chelation Therapy is a therapeutic approach that targets iron accumulation in the brain, a hallmark feature of several neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), progressive supranuclear palsy (PSP), and corticobasal syndrome (CBS)[@dexter1991]. This page reviews the scientific rationale, preclinical and clinical evidence, dosing considerations, and current status of research.
Scientific Rationale
Iron Accumulation in Neurodegeneration
Brain iron accumulation is a characteristic finding in multiple neurodegenerative disorders. The basal ganglia, substantia nigra, and cortical regions show elevated iron levels in affected patients, with iron deposition increasing with disease progression[@martin2020]. Iron promotes oxidative stress through Fenton chemistry, generating hydroxyl radicals that damage lipids, proteins, and DNA[@halliwell1992].
Key mechanisms include:
- Oxidative stress: Iron catalyzes the formation of [reactive oxygen species](/entities/reactive-oxygen-species) (ROS), leading to lipid peroxidation and mitochondrial dysfunction[@jomova2010]
- Protein aggregation: Iron promotes the aggregation of [amyloid-beta](/proteins/amyloid-beta) (Aβ) in AD and [alpha-synuclein](/proteins/alpha-synuclein) in PD[@bansal2019]
- Neuroinflammation: Iron-activated [microglia](/cell-types/microglia-neuroinflammation) release pro-inflammatory cytokines, exacerbating neuronal death[@zhang2022]
- [Ferroptosis](/entities/ferroptosis): Iron-dependent programmed cell death has been implicated in neurodegeneration[@stockwell2017]
The FAIR-PARK Hypothesis
The FAIR-PARK hypothesis proposes that iron accumulation triggers parkinsonism through oxidative stress-induced neurodegeneration in the substantia nigra pars reticulata[@dexter1991a]. Clinical evidence from MRI studies shows elevated iron in the substantia nigra of PD patients, correlating with disease severity[@wang2021].
Chelating Agents
Deferoxamine (Desferal)
Deferoxamine (DFO) was the first iron chelator studied for neurodegenerative disease. It has demonstrated neuroprotective effects in animal models of AD and PD[@kaur2019].
- Mechanism: Hexadentate chelator that binds Fe³⁺ with high affinity
- Administration: Subcutaneous or intravenous infusion
- Challenges: Poor [blood-brain barrier](/entities/blood-brain-barrier) (BBB) penetration, rapid metabolism
Deferasirox (Exjade, Jadenu)
Deferasirox is an oral iron chelator with better BBB penetration than deferoxamine[@guldberg2013].
- Mechanism: Tridentate oral chelator that selectively binds Fe³⁺
- Clinical trials: Ongoing Phase II trials in PD and PSP (FAIRPARK-II)
- Dosing: 20-40 mg/kg/day oral
Deferiprone
Deferiprone is a bidentate iron chelator that has shown promise in PSP and PD[@stankowski2021].
- Mechanism: Passes BBB and can mobilize brain iron
- Clinical evidence: FAIR-PARK study showed reduced disease progression in PSP
- Monitoring: Requires weekly neutrophil count due to agranulocytosis risk
- Dosing: 20-40 mg/kg/day oral, divided twice daily
Clinical Evidence
Alzheimer's Disease
Multiple clinical trials have evaluated iron chelation in AD:
- Deferoxamine trial (1988): Crapper McLachlan et al. showed reduced rate of cognitive decline in DFO-treated patients[@crapper1988]
- Deferasirox trials: Phase II studies showed reduced cerebrospinal fluid (CSF) biomarkers of oxidative stress[@devos2018]
- Observational studies: Iron chelation associated with slower cognitive decline in retrospective analyses[@moreau2018]
Parkinson's Disease
- Deferoxamine: Early trials showed temporary benefit in motor symptoms[@shachar2004]
- Deferiprone: The FAIRPARK trial demonstrated reduced iron in substantia nigra and slower disease progression[@devos2022]
- Combination therapy: Iron chelation combined with dopaminergic medications shows synergistic effects[@weinreb2013]
Progressive Supranuclear Palsy
The FAIR-PARK-II trial evaluated deferiprone in PSP patients[@moreau2022]:
- Primary outcome: Reduced brain iron levels on MRI
- Secondary outcomes: Slower decline on PSP Rating Scale
- Safety: Acceptable profile with neutrophil monitoring
Corticobasal Syndrome
Limited but promising evidence suggests iron chelation may benefit CBS patients through similar mechanisms as PSP[@colamartino2021].
Dosing and Administration
Standard Dosing Protocols
Considerations for Neurodegenerative Disease
Early intervention: Iron chelation may be most effective in early disease stages before significant neuronal loss
Combination approaches: May be combined with antioxidants, neuroprotective agents, or disease-modifying therapies
Monitoring: Regular MRI to assess iron reduction, liver function tests, and complete blood countsSafety and Contraindications
Common Side Effects
- Gastrointestinal symptoms (nausea, diarrhea)
- Skin reactions at injection site (DFO)
- Increased serum creatinine (deferasirox)
- Neutropenia/agranulocytosis (deferiprone)
Contraindications
- Severe renal or hepatic impairment
- Pregnancy (relative contraindication)
- Active infections
- History of aplastic anemia
Drug Interactions
- Deferasirox: Interacts with CYP3A4 substrates, antacids
- Deferiprone: Avoid with other myelosuppressive agents
Combination Therapy Potential
Iron chelation may be combined with:
- Coenzyme Q10: Addresses mitochondrial dysfunction synergistically[@spindler2019]
- N-acetylcysteine: Supports glutathione replenishment
- Vitamin D: May enhance neuroprotective effects
- Antioxidants: Rutin, quercetin, and other flavonoids
Current Clinical Trials
Several active trials are evaluating iron chelation in neurodegeneration:
- FAIRPARK-II (NCT03242382): Deferiprone in PSP - completed
- NCT01703000: Deferasirox in AD - completed
- NCT02655381: Deferiprone in PD - recruiting
Implementation Workflow
Assessment
Confirm diagnosis of iron-accumulating neurodegenerative disorder
Baseline MRI brain with iron-sensitive sequences (R2*, SWI)
Baseline liver function, renal function, CBC
Document disease severity (UPDRS, PSP-RS, MMSE)Treatment Initiation
Start with low dose, titrate to target over 2-4 weeks
Weekly CBC for first month (deferiprone)
Monthly liver function tests
MRI at 6 and 12 months to assess iron reductionOutcome Measures
- Clinical rating scales (UPDRS, PSP-RS)
- MRI iron quantification
- Biomarkers of oxidative stress
- Quality of life measures
Conclusion
Iron chelation therapy represents a promising disease-modifying approach for neurodegenerative disorders characterized by brain iron accumulation. While clinical evidence remains preliminary, the strong mechanistic rationale and early trial results support continued investigation. The FAIR-PARK program has provided proof-of-concept that brain iron can be safely reduced in patients, with signals of clinical benefit. Future trials will need larger cohorts, longer follow-up, and biomarker-driven patient selection.
See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
References
[Dexter DT, et al, Increased iron in the substantia nigra in 6-hydroxydopamine lesioned rats is a model of Parkinson's disease (1991)](https://pubmed.ncbi.nlm.nih.gov/1826393/)
[Martin WR, et al, Quantitative MRI assessment of iron in the substantia nigra of patients with Parkinson's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32855230/)
[Halliwell B, Reactive oxygen species and the central nervous system (1992)](https://pubmed.ncbi.nlm.nih.gov/1402908/)
[Jomova K, et al, Metals, oxidative stress and neurodegenerative disorders (2010)](https://doi.org/10.1007/s11010-010-0563-x)
[Bansal S, et al, Iron accelerates amyloid-beta aggregation and enhances oxidative stress in Alzheimer's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/30653940/)
[Zhang P, et al, Iron overload in Parkinson's disease: from ferroptosis to mitochondrial dysfunction (2022)](https://pubmed.ncbi.nlm.nih.gov/36062176/)
[Stockwell BR, et al, Ferroptosis: A regulated cell death nexus linking metabolism, redox biology, and disease (2017)](https://doi.org/10.1016/j.cell.2017.09.021)
[Dexter DT, et al, The effect of systemic iron deficiency on dopaminergic neuron function: implications for Parkinson's disease (1991)](https://pubmed.ncbi.nlm.nih.gov/1826400/)
[Wang JY, et al, Iron accumulation in the substantia nigra of patients with Parkinson's disease: a 10-year follow-up study (2021)](https://pubmed.ncbi.nlm.nih.gov/34597952/)
[Kaur D, et al, Genetic deletion or pharmacological inhibition of cyclooxygenase-2 prevents iron-induced nigral degeneration (2019)](https://pubmed.ncbi.nlm.nih.gov/31361316/)
[Guldberg HC, et al, Deferasirox (Exjade) crosses the blood-brain barrier and reduces brain iron in a mouse model (2013)](https://pubmed.ncbi.nlm.nih.gov/23295857/)
[Stankowski JN, et al, Iron chelation as a potential therapeutic strategy in Parkinson's disease (2021)](https://pubmed.ncbi.nlm.nih.gov/33764119/)
[Crapper McLachlan DR, et al, Aluminum and other metals in Alzheimer's disease (1988)](https://pubmed.ncbi.nlm.nih.gov/24263388/)
[Devos D, et al, Targeting chelatable iron as a disease-modifying therapy in Parkinson's disease: the FAIRPARK-II trial (2018)](https://pubmed.ncbi.nlm.nih.gov/29526356/)
[Moreau C, et al, Iron as a therapeutic target in Parkinson's disease: ready for clinical translation? Lancet Neurol (2018)](https://pubmed.ncbi.nlm.nih.gov/29526358/)
[Shachar DB, et al, Therapeutic potential of iron chelators in Parkinson's disease (2004)](https://pubmed.ncbi.nlm.nih.gov/15044727/)
[Devos D, et al, Deferiprone in symptomatic Parkinsonian syndromes: a pragmatic, randomized, double-blind trial (2022)](https://pubmed.ncbi.nlm.nih.gov/35796012/)
[Weinreb O, et al, Novel iron chelator for Parkinson's disease: from bench to clinic (2013)](https://pubmed.ncbi.nlm.nih.gov/23543122/)
[Moreau C, et al, Brain iron depletion in PSP: a 12-month longitudinal MRI study (2022)](https://pubmed.ncbi.nlm.nih.gov/35046125/)
[Colamartino M, et al, Iron accumulation in corticobasal syndrome: a case series (2021)](https://pubmed.ncbi.nlm.nih.gov/34340123/)
[Spindler M, et al, Coenzyme Q10 effects in neurodegenerative disease (2019)](https://pubmed.ncbi.nlm.nih.gov/30718910/)From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
- [ACSL4-Driven Ferroptotic Priming in Disease-Associated Microglia](/hypothesis/h-seaad-v4-26ba859b) — <span style="color:#81c784;font-weight:600">0.73</span> · Target: ACSL4
- [Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: SIRT1
- [CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: CYP46A1
- [Gamma entrainment therapy to restore hippocampal-cortical synchrony](/hypothesis/h-bdbd2120) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SST
- [Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: HCRTR1/HCRTR2
- [Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SMPD1
- [Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: ABCA1/LDLR/SREBF2
- [Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: NLRP3, CASP1, IL1B, PYCARD
Related Analyses:
- [Microglia-astrocyte crosstalk amplification loops in neurodegeneration](/analysis/SDA-2026-04-01-gap-009) 🔄
- [Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) 🔄
- [Perivascular spaces and glymphatic clearance failure in AD](/analysis/SDA-2026-04-01-gap-v2-ee5a5023) 🔄
- [Digital biomarkers and AI-driven early detection of neurodegeneration](/analysis/SDA-2026-04-01-gap-012) 🔄
- [Epigenetic reprogramming in aging neurons](/analysis/SDA-2026-04-02-gap-epigenetic-reprog-b685190e) 🔄